SK Plasma and Andong City Sign MOU for Plasma Fractionation Infrastructure Investment

On July 15, SK Plasma, a company specializing in blood products, announced that it will expand its storage facilities in partnership with Andong City, Gyeongbuk, to ensure a stable supply of plasma fractionation products.

SK Plasma CEO Seungjoo Kim (right) and Andong Mayor Kichang Kwon (left) are posing for a commemorative photo after signing the Memorandum of Understanding (MOU) for investment in plasma fractionation production infrastructure at Andong City Hall in Andong, Gyeongbuk on the 14th. SK Plasma

원본보기 아이콘

On July 14, SK Plasma signed a Memorandum of Understanding (MOU) with Andong City for an investment of approximately 12 billion KRW at the Andong City Hall communication room. This agreement aims to enhance supply stability and operational efficiency in response to rapidly changing market demand by expanding storage capacity at the Andong plant, while also contributing to revitalizing the local economy and creating jobs.

According to the MOU, SK Plasma plans to sequentially invest about 12 billion KRW by 2027 to build new freezing facilities for storing raw plasma and refrigeration facilities for finished pharmaceuticals on a 7,955.7-square-meter site near the existing Andong fractionation center. Additional facilities to improve production and operational efficiency, such as a materials warehouse and office space, are also planned. The expansion of facilities will be accompanied by the recruitment of new personnel.

SK Plasma began construction of its plant in the Gyeongbuk Bio Industry Complex in Andong in 2015 and commenced full-scale commercial production in 2018. The plant is equipped with production facilities capable of fractionating 600,000 liters of plasma annually and supplies essential pharmaceuticals such as albumin and immunoglobulin to both domestic and international markets.

Kichang Kwon, Mayor of Andong, stated, "This additional investment by SK Plasma marks a turning point that will enhance the competitiveness of the local bio industry and serve as an important driving force for sustainable growth. We will continue to strengthen our collaborative relationship by creating a business-friendly environment and providing administrative support."

Seungjoo Kim, CEO of SK Plasma, said, "With the expansion of storage facilities, we are now better positioned to flexibly produce and supply blood products in response to changing market demand. We will continue various collaborations with Andong City to stabilize the supply of blood products and promote the local bio industry."

Meanwhile, SK Plasma is constructing a plasma fractionation center in Karawang, Indonesia, with an annual processing capacity of 600,000 liters, aiming to begin operations in the fourth quarter of 2026. To minimize any supply gap before the plant becomes operational, the company plans to import plasma secured in Indonesia to Korea and supply blood products through contract manufacturing at the Andong plant.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.